8-K current report · filed Aug 13, 2026

Cullinan Therapeutics, Inc. (CGEM) 8-K Current Report: August 13, 2026

Item 8.01Item EX-99.1Item 7.01CGEM overview

Short answer

Cullinan Therapeutics, Inc. (CGEM) filed an 8-K current report with the SEC on August 13, 2026 reporting Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1), Item 7.01 (Regulation FD Disclosure). Phase 3 REZILIENT3 trial met its primary progression-free survival endpoint at planned interim analysis.

Cullinan Therapeutics, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 7.01 · Regulation FD Disclosure

  • Phase 3 REZILIENT3 trial met its primary progression-free survival endpoint at planned interim analysis
  • Zipalertinib plus platinum chemotherapy outperformed chemotherapy alone in first-line EGFR exon 20 insertion NSCLC
  • Positive pivotal-trial result supports potential regulatory filings and expands zipalertinib’s frontline treatment opportunity
  • Taiho partnership adds commercialization resources, while detailed efficacy and safety data remain in Exhibit 99.1

Item 8.01 · Other Events

  • REZILIENT3 met its primary PFS endpoint, supporting zipalertinib’s efficacy in first-line EGFR exon 20 insertion NSCLC
  • Statistically significant and clinically meaningful PFS improvement in the zipalertinib-containing arm
  • Manageable observed safety profile, with the Independent Data Monitoring Committee recommending trial unblinding
  • Taiho and Cullinan plan U.S. approval pursuit for zipalertinib plus platinum chemotherapy, pending FDA discussions
  • Full trial results slated for presentation at an upcoming international medical conference

Item EX-99.1 · Exhibit EX-99.1

  • Phase 3 REZILIENT3 met its primary progression-free survival endpoint at planned interim analysis in first-line EGFR exon 20 insertion NSCLC
  • Zipalertinib plus platinum chemotherapy delivered statistically significant, clinically meaningful PFS improvement versus chemotherapy alone
  • Trial enrolled 285 patients; observed safety for the combination arm was described as manageable
  • Independent monitoring committee recommended unblinding; continued efficacy and safety follow-up remains
  • Positive data support planned U.S. regulatory discussions and potential approval pursuit, though zipalertinib remains investigational

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Cullinan Therapeutics, Inc. 8-K filings

Get the next CGEM 8-K as it lands

Follow CGEM for push alerts, or ask the research agent what this filing means.